ଲିନାଗ୍ଲିପ୍ଟିନ

ଲିନାଗ୍ଲିପ୍ଟିନ
Clinical data
Pronunciation	/ˌlɪnəˈɡlɪptɪn/ LIN-ə-GLIP-tin
Trade names	Tradjenta, Trajenta, others
Synonyms	BI-1356
AHFS/Drugs.com	monograph
MedlinePlus	a611036
data	EU EMA: yes; US DailyMed: Linagliptin;
Pregnancy; category	US: B (No risk in non-human studies) ; ;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	~30% (Tmax = 1.5 hours)
Protein binding	75–99% (concentration-dependent)
Metabolism	Minimal (~10% metabolized)
Metabolites	Pharmacologically inactive
Elimination half-life	~24 hours
Excretion	Feces (80%), urine (5%)
Identifiers
	IUPAC name 8-[(3R)-3-Aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione;
Chemical and physical data
Formula	C25H28N8O2
Molar mass	୪୭୨.୫୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C;
	InChI InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1 ; Key:LTXREWYXXSTFRX-QGZVFWFLSA-N ;
(verify)

ଲିନାଗ୍ଲିପ୍ଟିନ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଟ୍ରାଜେଣ୍ଟା, ହେଉଛି, ମଧୁମେହ ଟାଇପ ୨ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ଏକ ଔଷଧ |^[୨] ପ୍ରାରମ୍ଭିକ ଚିକିତ୍ସା ଭାବରେ ମେଟଫର୍ମିନ୍ ଏବଂ ସଲଫୋନିଲୁରିଆ ଅପେକ୍ଷା ଏହା ସାଧାରଣତଃ କମ୍ ପସନ୍ଦ କରାଯାଏ | ^[୩] ^[୪] ଏହା ବ୍ୟାୟାମ ଏବଂ ଉପ‌ଯୁକ୍ତ ଖାଦ୍ୟ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ | ^[୩] ଟାଇପ୍ ୧ ମଧୁମେହରେ ଏହା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୩] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନାକ ଏବଂ ଗଳାର ପ୍ରଦାହ ହୋଇପାରେ | ^[୨] ଗମ୍ଭୀର ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଞ୍ଜିଓଇଡିମା, ଅଗ୍ନାଶୟ ପ୍ରଦାହ, ଗଣ୍ଠି ଯନ୍ତ୍ରଣା ହୋଇପାରେ | ^[୪] ^[୩] ଗର୍ଭାବସ୍ଥାରେ ଏବଂ ସ୍ତନ୍ୟପାନରେ ବ୍ୟବହାର କରିବା ସୁପାରିଶ କରାଯାଏ ନାହିଁ | ^[୫] ଲିନାଗ୍ଲିପ୍ଟିନ୍ ହେଉଛି ଏକ ଡାଇପେପ୍ଟାଇଲ ପେପ୍ଟିଡେଜ-୪ ଇନହିବିଟର (DPP-4 inhibitors) | ^[୩] ଏହା ଅଗ୍ନାଶୟରେ ଇନସୁଲିନର ଉତ୍ପାଦନ ବୃଦ୍ଧି ଏବଂ ଗ୍ଲୁକାଗନର ଉତ୍ପାଦନ ହ୍ରାସ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ | ^[୩]

୨୦୧୧ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଲିନାଗ୍ଲିପ୍ଟିନ୍ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୨] ୨୦୧୯ରେ ଯୁକ୍ତରାଜ୍ୟରେ ମୂଲ୍ୟ ବାବଦ ପ୍ରାୟ ୩୩ ପାଉଣ୍ଡ ଖର୍ଚ୍ଚ ହୋଇଥାଏ। ^[୪] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ହୋଲସେଲ ମୂଲ୍ୟ ପ୍ରାୟ ୩୯୧ ଡଲାର ଅଟେ। । ^[୬] ୨୦୧୭ରେ, ଏହା ଯୁକ୍ତରାଷ୍ଟ୍ରର ୨୦୦ତମ ସାଧାରଣ ପ୍ରେସକ୍ରିପସନ୍ ଔଷଧ ଥିଲା, ଯେଉଁଥିରେ ଦୁଇ ଲକ୍ଷରୁ ଅଧିକ ପ୍ରେସକ୍ରିପସନ୍ ଥିଲା | ^[୭] ^[୮]

ଆଧାର

↑ "Tradjenta (linagliptin) Tablets. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA. Archived (PDF) from the original on 6 November 2016. Retrieved 10 November 2016.
↑ ^୨.୦ ^୨.୧ ^୨.୨ "Linagliptin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Linagliptin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.
↑ ^୪.୦ ^୪.୧ ^୪.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 680. ISBN 9780857113382.
↑ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 680. ISBN 9780857113382.
↑ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.
↑ "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.
↑ "Linagliptin - Drug Usage Statistics". ClinCalc. Archived from the original on 10 July 2020. Retrieved 11 April 2020.

[PI-1] "Tradjenta (linagliptin) Tablets. Full Prescribing Information" (PDF). Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA. Archived (PDF) from the original on 6 November 2016. Retrieved 10 November 2016.

[AHFS2019-2] ୨.୦ ^୨.୧ ^୨.୨ "Linagliptin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.

[autogen1-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ ^୩.୫ ^୩.୬ "Linagliptin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). American Society of Health-System Pharmacists. Archived from the original on 6 April 2019. Retrieved 6 April 2019.

[BNF76-4] ୪.୦ ^୪.୧ ^୪.୨ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 680. ISBN 9780857113382.

[autogen4-5] British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 680. ISBN 9780857113382.

[NADAC2019-6] "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services (in ଇଂରାଜୀ). Archived from the original on 2019-03-06. Retrieved 3 March 2019.

[ref-7] "The Top 300 of 2020". ClinCalc. Archived from the original on 12 February 2021. Retrieved 11 April 2020.

[ref1-8] "Linagliptin - Drug Usage Statistics". ClinCalc. Archived from the original on 10 July 2020. Retrieved 11 April 2020.

[୨]

[୩]

[୪]

[୧]

[୫]

[୬]

[୭]

[୮]

Clinical data

Pronunciation	/ˌlɪnəˈɡlɪptɪn/ LIN-ə-GLIP-tin
Trade names	Tradjenta, Trajenta, others
Synonyms	BI-1356
AHFS/Drugs.com	monograph
MedlinePlus	a611036
data	EU EMA: yes US DailyMed: Linagliptin
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	~30% (T_max = 1.5 hours)
Protein binding	75–99% (concentration-dependent)
Metabolism	Minimal (~10% metabolized)
Metabolites	Pharmacologically inactive
Elimination half-life	~24 hours
Excretion	Feces (80%), urine (5%)^[୧]
Identifiers
IUPAC name 8-[(3R)-3-Aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Chemical and physical data
Formula	C₂₅H₂₈N₈O₂
Molar mass	୪୭୨.୫୫ g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
InChI InChI=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1^N Key:LTXREWYXXSTFRX-QGZVFWFLSA-N^N
(verify)